CHO Pharma, Inc. (TPEX:6586)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
53.80
-3.40 (-5.94%)
May 8, 2026, 2:00 PM CST
Market Cap11.68B +23.7%
Revenue (ttm)1.43M -60.0%
Net Income-290.01M
EPS-1.36
Shares Out214.01M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume843,253
Average Volume1,313,309
Open57.10
Previous Close57.20
Day's Range52.10 - 57.80
52-Week Range22.75 - 68.30
Beta0.52
RSI60.44
Earnings DateMay 13, 2026

About CHO Pharma

CHO Pharma, Inc., engages in research and development of biotechnology in Taiwan. It develops glycoengineering platform technologies, including SAR-based glycoengineered biobetters; glycosite-specific antibody-drug conjugates (ADCs); novel antibodies and vaccines targeting novel carbohydrate antigens; and programs using its glycoengineering technologies. The company also provides CHOptimax, an in vitro enzymatic one-pot process that converts naked antibodies into glycoengineered biobetter or ADC. In addition, the company develops CHO-H01, which... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6586
Full Company Profile

Financial Performance

In 2025, CHO Pharma's revenue was 1.43 million, a decrease of -60.03% compared to the previous year's 3.58 million. Losses were -290.01 million, 36.6% more than in 2024.

Financial Statements